Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

圣地亚哥 - Viking Therapeutics, Inc. (NASDAQ: VKTX)过去一年股价上涨了令人印象深刻的114%，该公司已经启动了VK2735的二期临床试验，这是一种旨在治疗肥胖症和相关代谢疾病的口服药物。根据 InvestingPro ...

圣地亚哥—根据最近的SEC文件显示，Viking Therapeutics, Inc. (NASDAQ:VKTX)的首席财务官Zante Greg最近出售了公司大量股票。Greg于2025年1月6日在两笔独立交易中共售出50,309股。这些股票的售价在42.6888美元至43.3194美元之间，总计约215万美元。此次交易发生之际，Viking的股票交易价格高于其 InvestingPro ...

COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

Highlights,Viking Therapeutics CEO Brian Lian to present on January 13, 2025, at the J.P. Morgan Healthcare Conference,The ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.